RIBOMIC confirms positive results from SUSHI study in wet AMD patients
Category: #health  | By Mateen Dalal  | Date: 2019-06-19 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

RIBOMIC confirms positive results from SUSHI study in wet AMD patients
  • Phase 1/2a trial of RBM-007 was successfully conducted, yielding top-line results
     
  • Seven out of nine subjects showed a considerable improvement in Central Retinal Thickness

Clinical stage pharmaceutical company RIBOMIC has recently unveiled positive top-line results from its SUSHI study, a Phase 1/2a single ascending dose trial of anti-FGF2 aptamer RBM-007, in nine patients with wet Age-Related Macular Degeneration (wet AMD).

Apparently, subjects enrolled for the SUSHI study had been diagnosed with wet AMD that showed very little response to the previously given intravitreal anti-VEGF treatment. Secondary results at the end of the primary study endpoint of 28 days showed notable indication regarding bioactivity of RBM-007.

Seven out of nine patients responded to RBM-007, in terms of Best-Corrected Visual Acuity (BCVA) or ≥50 µm progress in Central Retinal Thickness on optical coherence tomography (OCT), reports suggested.

Reportedly, wet age-Related Macular Degeneration (AMD) accounts for a major cause of blindness in the United States and Europe. The condition involves formation of anomalous and leaky new blood vessels beneath the retina, known as choroidal neovascularization. The leakage of fluid from vessels causes severe and rapid loss of vision.

RBM-007 is an oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. Subjects’ eyes were administered with a single injection of RBM-007 in three subsequent dose cohorts (3 subjects/cohort): 0.2 mg (Cohort 1), 1.0 mg (Cohort 2) and 2.0 mg (Cohort 3). The primary study was concluded at Day 28, with follow-up through Day 56.

Yoshikazu Nakamura, CEO and president, RIBOMIC Inc., was reportedly quoted saying that they were very encouraged by the results of SUSHI study. It was designed as a first-in-human, single-dose safety study and had surpassed their expectations from the standpoint of bioactivity.

Yusuf Ali, CEO, RIBOMIC USA Inc., said SUSHI study had demonstrated that single dose of intravitreal RBM-007 up to 2 mg dose was well-tolerated in subjects with wet AMD, as showcased  by clinical efficacy in several subjects as measured by BCVA and OCT thickness. This suggests FGF2 was an important target in the pathogenesis of wet AMD.

 

Source Credits:  https://www.businesswire.com/news/home/20190617005273/en/RIBOMIC-Announces-Positive-Top-Line-Results-Phase-12a

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

NEA AND SLA SIGN MOU TO SHARE GLOBAL NAVIGATION SATELLITE SYSTEM (GNSS)-DERIVED MOISTURE DATA FOR WEATHER MONITORING APPLICATION

NEA AND SLA SIGN MOU TO SHARE GLOBAL NAVIGATION SATELLITE SYSTEM (GNSS)-DERIVED MOISTURE DATA FOR WEATHER MONITORING APPLICATION

By Mateen Dalal

Singapore, 2 August 2022 – The National Environment Agency (NEA) and the Singapore Land Authority (SLA) have signed a Memorandum of Understanding (MOU) to develop the use of Global Navigation Satellite System (GNSS) data obtained from SLA&rsqu...

Baidu launches Apollo RT6; seeks expansion of its robotaxi fleet

Baidu launches Apollo RT6; seeks expansion of its robotaxi fleet

By Mateen Dalal

Baidu, a leading China-based artificial intelligence (AI) company and search engine, has reportedly uncovered its most recent electric autonomous driving vehicle. As per credible sources, the new vehicle, Apollo RT6, will be a part of the robotaxi...

ParTech launches PAR Infinity for improvised technological solutions

ParTech launches PAR Infinity for improvised technological solutions

By Mateen Dalal

ParTech, Inc. a leading international provider of combined commerce for enterprise restaurants, has reportedly declared the launch of PAR Infinity. As per sources, the subscription centric hardware offering integrates PAR’s purposely develop...